• 3X FLAG Peptide: Practical Purification Workflows

  2026-09-27

  Use the 3X FLAG peptide as a sequence-matched competitor for FLAG affinity workflows, and as a control for antibody-based detection—not as a substitute for encoding the tag in your protein construct. This guide connects practical purification and assay choices to recent work on influenza host factors while clearly separating the study’s findings from the peptide’s demonstrated uses.

• PTH (1-34) in Spatial Kidney Assembloid Research

  2026-09-26

  Explore how Parathyroid hormone (1-34) (human) can support carefully bounded studies of endocrine signaling in spatially organized kidney assembloids. The focus is not simply peptide potency, but how tissue architecture, receptor context, and whole-body calcium physiology shape experimental interpretation.

• Resazurin Sodium Salt in Gut–Cell Assays

  2026-09-25

  Use Resazurin sodium salt to track metabolic activity in gut-cell experiments—but interpret fluorescence as a redox-linked signal, not a direct cell count. This workflow connects microbiota-driven GLP-1 research to practical assay controls, optimization, and orthogonal validation.

• 3X FLAG Peptide for Autophagy Assay Design

  2026-09-25

  Learn how the 3X (DYKDDDDK) Peptide can support studies of selective autophagy without confusing tag detection with evidence of protein turnover. This assay-centered guide uses OTUD7B–p62–IRF3 biology to explain controls, interpretation limits, and metal-sensitive antibody decisions.

• 4-Ethylphenyl Sulfate: Applied Research Workflows

  2026-09-24

  Use 4-ethylphenyl sulfate to isolate the effects of a single microbiota-derived metabolite in renal biomarker, biomaterial adsorption, and gut–brain studies. This practical guide pairs matrix-aware preparation with assay controls and highlights where evidence supports a hypothesis—not a clinical conclusion.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-09-24

  The study links elevated miR-18a with reduced ALOXE3 activity, identifying a pathway that can weaken ferroptotic cell death while promoting glioblastoma cell migration. Its combination of tumor-model, cell-based, and lipid-mediator evidence positions the miR-18a/ALOXE3 axis as a mechanistic connection between lipid metabolism and GBM progression, while leaving its therapeutic potential to be tested.

• MK-4827 (Niraparib): PARP Inhibition Research

  2026-09-23

  MK-4827, also known as Niraparib, is a research inhibitor of PARP-1 and PARP-2 that blocks a DNA damage repair pathway. Its reported biochemical potency and BRCA-mutant cell findings support cancer research, while a hepatocellular carcinoma study provides a separate, context-specific rationale for studying spliceosome regulation alongside PARP inhibition.

• Gepotidacin Mechanism at S. aureus Gyrase

  2026-09-23

  The reference study defines how gepotidacin inhibits Staphylococcus aureus gyrase through a mechanism distinct from that of fluoroquinolones. Biochemical assays and high-resolution structures show potent inhibition, persistent gyrase–DNA complexes, and predominantly single-stranded DNA cleavage, providing a mechanistic framework for studying antibacterial agents that can retain activity against fluoroquinolone-resistant bacteria.

• EPZ5676: A Selective DOT1L Inhibitor Workflow

  2026-09-22

  EPZ5676 enables a tightly controlled path from SAM-pocket inhibition to H3K79 methylation loss and leukemia-cell response. This workflow combines biochemical validation, MLL-rearranged models, orthogonal target-engagement assays, and immune-signature controls to improve interpretation and reproducibility.

• Tofacitinib Citrate: Immune Assay Workflows

  2026-09-22

  Build concentration-aware workflows with Tofacitinib citrate for JAK-STAT signaling, lymphocyte proliferation inhibition, and T-cell differentiation studies. A comparative endothelial-cell framework helps researchers separate useful anti-inflammatory activity from high-dose vascular stress signals.

• GS-4997 and Tubulointerstitial Injury in Lupus Nephritis

  2026-09-21

  The reference study identifies ASK1 signaling as a pharmacologically tractable driver of tubulointerstitial injury in lupus nephritis. In female MRL/lpr mice and LPS-stimulated HK-2 cells, GS-4997 reduced inflammation, fibrosis, tubular damage, and downstream p38/JNK activation, supporting further mechanistic investigation rather than establishing a clinical treatment.

• IL-1β Tetrapeptide Controls Inflammatory Caspases

  2026-09-21

  The reference preprint identifies the P4–P1 tetrapeptide adjacent to the canonical IL-1β cleavage site as a determinant of recruitment and productive processing by inflammatory caspases. It also reports direct IL-18 cleavage by human caspases-4/-5 and an apparently inactive IL-1β fragment generated by non-canonical caspases, refining how inflammasome proteases should be interpreted in cytokine and pyroptosis studies.

• Phosphoproteomic Adaptation to Cabozantinib in RCC

  2026-09-20

  This study distinguishes acute from chronic Cabozantinib exposure in renal cell carcinoma by integrating quantitative phosphoproteomics with migration and invasion assays. Its main contribution is a timescale-aware model in which broad cytostatic phosphorylation changes evolve into selective adhesion-, stress-, and MAPK/AP-1-associated remodeling while MET activation-loop phosphorylation remains suppressed.

• ATRA Sensitizes Ovarian Cancer to Niraparib

  2026-09-19

  The reference study shows that all-trans retinoic acid can reduce cisplatin-induced resistance to niraparib in epithelial ovarian cancer models. Its treatment-sequence findings connect retinoid signaling with suppression of an ALDH1A1–NAMPT–PARP1–CHK1 and NAD+-associated resistance state, supporting a maintenance strategy that combines ATRA with PARP inhibition.

• Silymarin Workflows for Translational Research

  2026-09-19

  Silymarin, a chemically diverse milk thistle extract, gives researchers a practical probe for oxidative injury, tumor biology, metabolic dysfunction, and selected antiviral target assays. This guide turns its solubility, mixture composition, and redox activity into controlled workflows with dose-selection, orthogonal validation, and troubleshooting strategies.

8552 records 1/571 page Next 12345 下5页 Last page